Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200110005103/en/
https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-and-bristol-myers-squibb-amend-strategic
Lilly to acquire Dermira for $1.1 billion, expanding its portfolio of Phase 3 medicines with the addition of lebrikizumab, an IL-13antibody being studied in Phase 3 for the treatment of moderate-to-severe atopic dermatitis
Acquisition also includes QBREXZA, Dermira's medicated cloth for primary axillary hyperhidrosis
\
https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-dermira
yeah what a scum bag. Speaks of the quality of the Ariad board under Berger. lol
Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal
a non-binding proposal from a private equity fund to acquire a majority or all of the issued and outstanding shares of the Company for up to $7.00 per share.
http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-inc-received-non-binding-acquisition
Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001
https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-announces-organizational-changes-prioritize
every morning. just made some. you know how biotech can be in January!
Tomorrow morning in 2017 I was downstairs around 5am checking out the markets, any updates from Asia and Europe drinking coffee. Little did I know within the next cup of coffee Ariad would be halted pending news. I quickly did a twitter search and someone had posted Taketa buys Ariad $24. I never returned to that cup of coffee as I ran upstairs to tell my wife the news ...who had no idea why I was so excited at that time of the morning. I proceeded to tweet Adam Feuerstein, who had reviewed his 2016 bio hits and misses stating his Ariad call wasn't a hit or a miss cuz "It wasn't bought". and continuing to claim he was Right about slamming Ariad all year. I tweeted him that he may as well admit that he was Dead Wrong. He proceeded to retweet my tweet admitted Yes he was wrong. It was a fine day
Speaking of fielding offers from potential buyers, in the United States a target company isn't necessarily obligated to disclose any explorations of sale or negotiations prior to a binding agreement You can say the same on the other side where potential buyers have no duty to disclose in advance that they plan to buy someone. So in AUPH's case, we may never know if they have already fielded an array of offers and even debated accepting one around the Board table. In Ariad's case, Paris disclosed in SEC filings close to Feb 2017 that three offers were submitted by Taketa and the third was accepted on Dec 25 2016. Merry Christmas lol.
The only time a company must disclose the acquisition is after a binding agreement is sealed, a negotiation between both parties will directly cause a material event OR when a buyer first makes a toehold position and must file a schedule 13D if ownership is 5% or more...and refile after any material change like an ultimate takeout of remaining shares.
For all ARIAD fans, may this Bloomberg piece remind us how idiotic and greedy folks can be with insider trading. Great review of past events here
Global Insider-Trading Ring Linked to Trial of Pharma CEO’s Son
Lavidas allegedly part of scheme that made tens of millions
Stock tips exchanged for fruit-bar venture funding, U.S. says
https://www.bloomberg.com/news/articles/2020-01-06/global-insider-trading-ring-linked-to-trial-of-pharma-ceo-s-son
Happy New Year Aurinia longs. what a journey its been since many here loaded up early 2017. may 2020 be the best year yet for all of you. Cheers!
GSK:
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-complete-response-letter-from-us-fda-for-use-of-investigational-cabotegravir-and-rilpivirine-long-acting-regimen-in-the-treatment-of-hiv/
Lannett Receives FDA Approvals For Two Dosage Strengths Of Butalbital, Acetaminophen And Caffeine Capsules
http://lannett.investorroom.com/2019-12-23-Lannett-Receives-FDA-Approvals-For-Two-Dosage-Strengths-Of-Butalbital-Acetaminophen-And-Caffeine-Capsules
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyLâ„¢ in Prostate Cancer Achieved Primary Endpoint
Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance
- Company Expects to Submit an NDA to the FDA in the Second Half of 2020
- Conference Call at 8:00 AM Eastern Time
https://www.progenics.com
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
https://ir.intracellulartherapies.com/download-library
AZN. Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan demonstrated an impressive 14.8-month median duration of response and 16.4-month median progression-free survival
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/trastuzumab-deruxtecan-achieved-a-tumour-response-rate-of-60-in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial-11122019.html
thank you vid!
AUPH great news for LN patients. congrats longs. many ARIA alums holding AUPH.
congrats ariad alums and all auph longs. Thank you to Vidpok. please shoot him a note to reconnect . Great news for LN patients. Have a great night
DOVA traded $8.50-9 prior to that late June PR. Now $28. Congrats longs
guys- its a Russian best seller...time to double down.
Algernon Pharmaceuticals Announces Emoxypine (NP-178), a Top Selling Drug in Russia, as its Lead Drug for Inflammatory Bowel Disease
http://www.globenewswire.com/news-release/2019/08/02/1896228/0/en/Algernon-Pharmaceuticals-Announces-Emoxypine-NP-178-a-Top-Selling-Drug-in-Russia-as-its-Lead-Drug-for-Inflammatory-Bowel-Disease.html
ENANTA’S HCV COLLABORATION PARTNER ABBVIE RECEIVES APPROVAL BY THE EUROPEAN COMMISSION FOR MAVIRETâ„¢ (GLECAPREVIR/PIBRENTASVIR) TO SHORTEN TREATMENT DURATION TO EIGHT WEEKS FOR TREATMENT-NAÏVE HCV PATIENTS WITH COMPENSATED CIRRHOSIS
MAVIRETâ„¢ is now available as a shorter, 8-week, once-daily option for treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5 or 6
Marketing authorization is supported by 97.9 percent cure* rate across this group of patients with no reported virologic failures
Analysis evaluating MAVIRET as an 8-week, once-daily treatment option for treatment-naïve, compensated cirrhotic, GT3 HCV patients is ongoing
Glecaprevir, is one of the two direct-acting antivirals (DAAs) in MAVIRET and is Enanta’s second protease inhibitor developed and commercialized by AbbVie
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
'New York-based Bristol-Myers and Nektar agreed to a $1.85 billion strategic development and commercialization collaboration to develop medicines, including NKTR-214, for multiple cancer types in February 2018.'
https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-and-bristol-myers-squibb-announce-us-fda
Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
The 2015 partnership agreement between Alligator and Janssen has been terminated as a result of a strategic portfolio decision by Janssen to prioritize other assets.
The original partnership agreement with Janssen encompassed milestone payments up to a potential value of USD 695 million, with Alligator also eligible to receive tiered royalties on worldwide net sales upon successful launch and commercialization of ADC-1013. In addition to the funding of the program by Janssen over the past years, Alligator has received a USD 35 million upfront payment in 2015, and milestone payments of USD 11 million during the partnership.
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
Pimavanserin did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms (p=0.0940)
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
Spitfire, a portfolio company of Presidio Partners, was founded by John J. Nestor, Jr., Ph.D. and Velocity Pharmaceutical Development, LLC, for the sole purpose of developing the NASH drug candidate, SP-1373. Spitfire shareholders will receive an upfront payment of $5 million in Altimmune common stock and will be eligible to receive an additional $8 million in future regulatory and clinical milestones payable in cash or common stock. Spitfire shareholders are also eligible to receive up to $80 million in sales-based milestones. The issuance of common stock to satisfy the milestone payments is subject to stockholder approval in accordance with Nasdaq rules.
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
July 9, 2019 at 8:00 AM EDT
Download PDF
-Triggers $10 Million Milestone Payment to CytomX-
https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-second-target-selection-and
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
The target selection triggers a $10 million payment to CytomX from AbbVie. This is the second of two research targets available to AbbVie under the agreement. The companies are also advancing a clinical-stage asset, CX-2029, under a global co-development and licensing agreement.
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
Xiidra is the first and only prescription treatment approved for both signs and symptoms of dry eye disease with a mechanism of action that targets inflammation[2]
DOVA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR DOPTELET® (AVATROMBOPAG) FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication
Company to Host Conference Call at 9am EST
team yellow won
Shareholders Overwhelmingly Support Aurinia and its Board of Directors
Dissident Withdraws the Consents of its Nominees from Consideration Prior to the AGM
Aurinia Reaffirms its Commitment to Voclosporin and Creating Shareholder Value
DOVA currently T1 Halted, yesterday it PR'd
DOVA PHARMACEUTICALS ANNOUNCES EUROPEAN UNION MARKETING AUTHORIZATION FOR DOPTELET® (AVATROMBOPAG) FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE
Could halt be related to following quote from this PR? TBD
-Approval Based on Positive Efficacy and Safety Data from Two Phase 3 Clinical Trials-
-Company Intends to Partner for the European Commercialization of DOPTELET-
Esperion and Oberland Capital Announce $200 Million Funding Agreement
$125 Million Upfront, $25 Million Upon FDA Approval, and $50 Million at Esperion’s Option After Launch -
- Initial Mid-Single Digit Repayment Rate on U.S. Revenue to Step Down to Less than One Percent Rate Upon Certain Revenue Achievements -
- Esperion Reacquires 100% Revenue Rights Upon Repayment Completion -
- Conference Call and Webcast on Wednesday, June 26 at 4:30 p.m. Eastern Time -
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
51% of subjects in Cohort 2 achieved complete clearance of all treatable warts
VP-102 was well-tolerated with no serious adverse events reported
Common warts affect approximately 22 million people in the United States
Based on positive outcome, Verrica to request an ‘End of Phase 2’ meeting with the FDA
Management to host webcast and conference call tomorrow at 8 a.m. ET
Acer Therapeutics stock loses over 80% of its value after receiving CRL from FDA for Edsivo
https://www.marketwatch.com/story/acer-therapeutics-receives-crl-from-fda-for-edsivo-stock-halted-for-news-2019-06-25
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea
BPX-04 MET BOTH PRIMARY AND SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE
BPX-04 WAS WELL-TOLERATED; EFFICACY AND SAFETY PROFILE SUPPORT ADVANCEMENT INTO PHASE 3
ALDX--> Aldeyra Therapeutics Schedules Webcast And Conference Call To Announce Top-Line Results From The SOLACE Trial In Noninfectious Anterior Uveitis
http://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-schedules-webcast-and-conference-call-17
IMUX. up after-hours 84% as company prepares to present unpublished data
Preclinical data shows that IMU-838 appears selective towards those T cells producing high amounts of the pro-inflammatory cytokines, IFN? and IL-17.
In mixed lymphocyte reaction assays in combination with the anti-TNFa antibody infliximab, IMU-838 was shown to act synergistically with regard to the induction of regulatory macrophages, important for the efficacy of such anti-TNFa antibodies.
In addition to previous inflammatory bowel disease animal models, IMU-838 also demonstrated activity in a therapeutic animal colitis model with improvement of diarrhea score and significant TNFa reduction in the gut.
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, the Company is planning the divestiture of OTEZLA® (apremilast).
hahah I don't think Brad even has time for poker games, the guy is on an airplane more than pilots.
I tend to lean toward your post. CEO tries to shutdown the idea of animal health spin off as well as imply that larger M&A outside of Bolt-ons should ruled out. I rule out nothing Anything is possible with Big Fish Merck!
CTRV
The FDA provided positive feedback on ContraVir’s existing preclinical data of CRV431 and supports the study design for the NASH IND opening study.
Edesa Biotech stock rockets 140% after FDA gives go-ahead to early-stage trial for topical tx for CACD
https://www.marketwatch.com/story/edesa-biotech-stock-rockets-140-after-fda-gives-go-ahead-to-early-stage-trial-2019-06-20